Journal article
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Abstract
OBJECTIVES: A history of prior fracture is one of the strongest predictors of a future fragility fracture. In FREEDOM, denosumab significantly reduced the risk of new vertebral, non-vertebral, and hip fractures. We carried out a post-hoc analysis of FREEDOM to characterize the efficacy of denosumab in preventing secondary fragility fractures in subjects with a prior fracture.
METHODS: A total of 7808 women aged 60-90 years with a bone mineral …
Authors
Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A
Journal
Climacteric, Vol. 18, No. 6, pp. 805–812
Publisher
Taylor & Francis
Publication Date
November 2, 2015
DOI
10.3109/13697137.2015.1045484
ISSN
1369-7137